Skip to main content

Psyence Biomedical Ltd(PBM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.80
Day High6.94
Open:6.59
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
The Globe and Mail
Short sales on the TSX: What bearish investors are betting against
The TMX Market Centre is shown in Toronto, Wednesday, Sept. 11, 2024.
Tipranks
Psyence BioMed Begins Phase IIb Dosing of Psilocybin Candidate NPX-5 in Australian Cancer Adjustment Disorder Trial
GlobeNewswire
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Tipranks
Psyence Biomedical Adds Intraday Equity Purchase Option in White Lion Financing Deal
GlobeNewswire
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Tipranks
Psyence BioMed Backs Prospective U.S. Ibogaine Review, Citing GMP Supply Leadership
Tipranks
Trump Trade: President to sign order on psychedelic used for PTSD
GlobeNewswire
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Tipranks
Psyence Biomedical Expands Australian Psilocybin Trial Network to Five Sites
GlobeNewswire
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
GlobeNewswire
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Tipranks
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
GlobeNewswire
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Tipranks
Psyence Biomedical Finalizes PsyLabs Share Swap, Settlement-Linked Loan and Board Changes
Tipranks
Psyence Biomedical Cedes 49.98% Stake to PsyLabs in US$5 Million Share Swap
GlobeNewswire
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Tipranks
Psyence Biomedical Shareholders Approve Board, Auditor and Share Consolidation Authority
GlobeNewswire
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Tipranks
Psyence Biomedical Ratifies Put Option Deal With PsyLabs to Secure Psychedelic Supply
GlobeNewswire
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
Tipranks
Psyence Biomedical Settles Shareholder Dispute With KAOS Capital
GlobeNewswire
Psyence BioMed Announces Settlement of Shareholder Litigation
Tipranks
Psyence Biomedical Sets February 2 Effective Date for 1-for-6.25 Reverse Stock Split
GlobeNewswire
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Tipranks
Psyence Biomedical Reschedules Shareholder Meeting After Quorum Shortfall
GlobeNewswire
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
GlobeNewswire
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Tipranks
Psyence BioMed Sets January 20, 2026 Start Date for 1-for-6.25 Reverse Stock Split
GlobeNewswire
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Tipranks
Psyence Biomedical Board Backs 2026 Strategy and Potential Share Buyback Program
GlobeNewswire
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Tipranks
Psyence Biomedical Calls January 22, 2026 Shareholder Meeting to Vote on Financials, Board and Share Consolidation

Profile

Psyence Biomed is a life science biotechnology company which focus on natural psychedelics. The company's operating divisions include Psyence Production, Psyence Therapeutics and Psyence Function which operates in Canada, the United Kingdom, Southern Africa, Australia and a presence in the United States. Psyence Biomed, formerly known as Newcourt Acquisition Corp, is based in NEW YORK.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.